Trial · NCT02154243
An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty
NCT02154243, Not applicable, Terminated, Hospital for Special Surgery, New York; results first posted 2017-07-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty. Trials, record NCT02154243. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02154243
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty
- NCT number
- NCT02154243
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 13 participants, actual
- Lead sponsor
- Hospital for Special Surgery, New York
- Conditions
- Orthostatic Hypotension
- Interventions
- Midodrine, Intravenous fluid bolus
- First posted
- 2014-06-03
- Last updated
- 2017-07-31
- Results first posted
- 2017-07-31
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Orthostatic Hypotension Questionnaire Score | From baseline assessment to post-intervention (30 min, 1 hr, 2 hrs, 3 hrs, 4 hrs) | |
| Secondary | Length of Stay | Length of the hospital stay (average of 4 days) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Orthostatic Hypotension Questionnaire Score | From baseline assessment to post-intervention (30 min, 1 hr, 2 hrs, 3 hrs, 4 hrs) | DATA WAS NOT COLLECTED. STUDY TERMINATED EARLY. | ||
| SECONDARY | Length of Stay | Length of the hospital stay (average of 4 days) | DATA WAS NOT COLLECTED. STUDY TERMINATED EARLY. |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Orthostatic Hypotension Questionnaire Score | Midodrine | 0 | |||
| Change in Orthostatic Hypotension Questionnaire Score | Intravenous Fluid Bolus | 0 | |||
| Change in Orthostatic Hypotension Questionnaire Score | Control (no Intervention) | 0 | |||
| Length of Stay | Midodrine | 0 | |||
| Length of Stay | Intravenous Fluid Bolus | 0 | |||
| Length of Stay | Control (no Intervention) | 0 |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Midodrine | 5 | |
| Overall Study | STARTED | Intravenous Fluid Bolus | 4 | |
| Overall Study | STARTED | Control (no Intervention) | 4 | |
| Overall Study | COMPLETED | Midodrine | 5 | |
| Overall Study | COMPLETED | Intravenous Fluid Bolus | 4 | |
| Overall Study | COMPLETED | Control (no Intervention) | 4 | |
| Overall Study | NOT COMPLETED | Midodrine | 0 | |
| Overall Study | NOT COMPLETED | Intravenous Fluid Bolus | 0 | |
| Overall Study | NOT COMPLETED | Control (no Intervention) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Midodrine | ||
| Total, all-cause mortality | Intravenous Fluid Bolus | ||
| Total, all-cause mortality | Control (no Intervention) | ||
| Total, other adverse events | Midodrine | 0 | 5 |
| Total, other adverse events | Intravenous Fluid Bolus | 0 | 4 |
| Total, other adverse events | Control (no Intervention) | 0 | 4 |
| Total, serious adverse events | Midodrine | 0 | 5 |
| Total, serious adverse events | Intravenous Fluid Bolus | 0 | 4 |
| Total, serious adverse events | Control (no Intervention) | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02154243
GET https://conductscience.org/api/trials/v1/NCT02154243/registered